Standard BioTools Inc. Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants
Standard BioTools Inc. (LAB) reported Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants of 11.69 million shares for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-11.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants · last filed 2025-03-11
- Standard BioTools Inc. incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2024-03-31 was 11.69M shares.
- Standard BioTools Inc. incremental common shares attributable to dilutive effect of call options and warrants for fiscal 2024 was 11.69M shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 3 month | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 6 month | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 9 month | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 12 month |
|---|---|---|---|---|
| 2024-12-31 | 11.69M shares 10-K · filed 2025-03-11 | |||
| 2024-09-30 | 11.69M shares 10-Q · filed 2024-11-06 | |||
| 2024-06-30 | 11.69M shares 10-Q · filed 2024-08-06 | |||
| 2024-03-31 | 11.69M shares 10-Q · filed 2024-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |